These studies may affect future patient care, as no current therapy for CVD provides the unique combination of potential actions proposed for GLP-1R agonists: improved glucose control with minimal hypoglycemia; improved endothelial function; reduced body weight, BP and serum triglycerides; improved recovery from ischemia; and improved hemodynamics in patients with reduced contractile function. This evidence concerns the gene GLP1R and Hypoglycemia.